Home / Healthcare/ GSK’s new triple lung drug beats other modern inhalers in study

GSK’s new triple lung drug beats other modern inhalers in study


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 27 September 2017 00:00


London (Reuters): GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.

Britain’s biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair.

Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca’s long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

The latest clinical trial, however, compares Trelegy to two more modern two-drug combinations and was seen as a more critical test for doctors wanting to know if the new product really delivers an added benefit.

The IMPACT study, which involved 10,355 patients, showed Trelegy delivered statistically significant reductions in the rate of annual exacerbations, or attacks, compared with both Breo and Anoro, two other relatively new GSK medicines.

GSK and its partner Innoviva plan to submit the latest data from the so-called IMPACT trial to regulatory authorities from the second quarter of 2018, with the aim of expanding the indicated patient population for Trelegy.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

22 June 1941: Operation Barbarossa

Friday, 22 June 2018

When Adolf Hitler founded his Third Reich in January of 1933 there was a decisive ‘quickening’ of history towards the cataclysmic


Why we’re not so keen to keep nepotism in the family

Friday, 22 June 2018

Some years ago, when the then President of Sri Lanka came in for calumny for having his son accompany him in a prominent


Everything about Trump’s diplomacy is commercial

Friday, 22 June 2018

President Trump is repeatedly boasting about his success in negotiating with North Korea. For decades and through


A brief guide to the legal system of China

Thursday, 21 June 2018

The law of the People’s Republic of China (PRC) is officially referred to as the “socialist legal system with Chinese characteristics”. The formation and development of the socialist legal system with Chinese characteristics are compatible with


Columnists More